Aldevron Collaborates with TriLink BioTechnologies for CleanCap mRNA Capping Technology
Shots:
- TriLink & Aldevron have entered into a non-exclusive license & supply agreement for TriLink’s patented CleanCap mRNA capping tech, allowing Aldevron’s clients to use it for developing mRNA-based therapeutics & vaccines
- As per the agreement, TriLink will provide CleanCap M6, CleanCap AG 3’OMe, CleanCap AG, & CleanCap AU cap analogs to Aldevron for mRNA development & manufacturing from pre-clinical to P-III programs
- CleanCap tech generates optimal 5’Cap structures with ~95% efficiency, improving mRNA yield & process time over traditional methods, with studies showing that CleanCap M6 boosts mRNA expression by >30% vs enzymatic capping
Ref: BusinessWire | Image: TriLink & Aldevron
Related News:- Vanda Pharmaceuticals Enters into an Exclusive Global License Agreement with AnaptysBio to Develop and Commercialize Imsidolimab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
